TSXV: DVA
TORONTO, May 3, 2018 /CNW/ - Delivra Corp. ("Delivra", or
"the Company") today announced the publication of their analytical
evaluation of a variety of third-party over-the-counter hemp
consumer products for tetrahydrocannabinol ("THC") and cannabidiol
("CBD") content to further develop its internal expertise and
evaluate the consumer landscape.
The publication conducted out of Delivra's research lab in
Charlottetown, PEI and partially
funded by Skills-PEI and by the Atlantic Canada Opportunities
Agency, concluded that most third-party consumer products met the
federal guidelines on THC content. However, the levels of CBD were
higher than THC in multiple products and reflects the lack of
federally mandated CBD testing of hemp-based finished products. As
a tool, the testing method is amenable to a variety of consumer
products indicating its general applicability towards cannabis oils
and more complex materials like creams and edibles. Delivra is well
positioned to be a preferred Company of choice to provide the
standardization of testing for the cannabis industry. These results
have now been published in the respected peer-reviewed scientific
journal, PLOS ONE, under the title, "A reliable and validated
LC-MS/MS method for the simultaneous quantification of 4
cannabinoids in 40 consumer products". The article may be found at
the following link:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196396.
"This data underscores the variety of analytical expertise
Delivra has developed in response to the intended legalization of
cannabis-based products in Canada
and is aligned with several active agreements between Delivra and
third-party companies requesting our analytical and formulary
expertise. Combining Delivra's unique knowledge of delivery systems
with core analytical expertise prepares our Company for further
future opportunities in cannabis product development with a focus
on safety and consistency," said Dr. Joseph
Gabriele, CEO of Delivra.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company having a
proprietary transdermal delivery system platform that can shuttle
pharmaceutical and natural molecules through the skin, in a
targeted manner. Delivra manufactures and sells a growing line of
natural topical creams with the proprietary transdermal delivery
system platform under the LivReliefTM brand, for
conditions such as joint and muscle pain, nerve pain, varicose
veins, wound healing, and under the LivSportTM brand for
sports performance. LivReliefTM products are available
in pharmacies, grocery chains, and independent health food stores
across Canada, including, but not
limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall,
Pharmasave, London Drugs, and on-line at www.livrelief.com. In
parallel with its consumer products business, Delivra also has a
mandate to license its patent-pending, proprietary transdermal
delivery technology platform to pharmaceutical companies globally,
for the repurposing of pharmaceutical molecules transdermally to
treat a broad range of conditions, along with licensing its
over-the-counter products globally. Delivra is headquartered in
Hamilton, Ontario and has a
research and development laboratory in Charlottetown, PEI.
Further information on Delivra can be found at
www.delivracorp.comhttp://www.delivracorp.com/ and
www.livrelief.com.
Cautionary Note Regarding Forward-Looking Statements
This news release includes certain information and statements
about management's view of future events, expectations, plans and
prospects that constitute "forward-looking statements", which are
not comprised of historical facts. Forward-looking statements may
be identified by such terms as "believes", "anticipates",
"intends", "expects", "estimates", "may", "could", "would", "will",
or "plan", and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: the Company's revenues and financial
performance; the Company's drug research and development plans; the
timing of operations; and estimates of market conditions. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Delivra to differ materially from those
anticipated or implied in such forward-looking statements. The
Company believes that the expectations reflected in these
forward-looking statements are reasonable, but there can be no
assurance that actual results will meet management's expectations.
In formulating the forward-looking statements contained herein,
management has assumed that business and economic conditions
affecting Delivra will continue substantially in the ordinary
course and will be favourable to Delivra; that the Company will
continue to complete orders with existing customers and control
product pricing and expenses that clinical testing results will
justify commercialization of the Company's drug candidates; that
Delivra will be able to obtain all requisite regulatory approvals
to commercialize its drug candidates, that such approvals will be
received on a timely basis, and that Delivra will be able to find
suitable partners for development and commercialization of its
products and intellectual property on favourable terms. Although
these assumptions were considered reasonable by management at the
time of preparation, they may prove to be incorrect. Factors that
may cause actual results to differ materially from those
anticipated by these forward-looking statements include: the
ability of the Company to maintain existing product sales with
current customers at existing product pricing and expenses;
uncertainties associated with obtaining regulatory approval to
perform clinical trials and market products; the need to establish
additional corporate collaborations, distribution or licensing
arrangements; the ability of the Company to generate sales and
profits; the Company's ability to raise additional capital if and
when necessary; intellectual property disputes; increased
competition from pharmaceutical and biotechnology companies;
changes in equity markets, inflation, and changes in exchange
rates; and other factors as described in detail in Delivra's public
filings, all of which may be viewed on SEDAR (www.sedar.com). Given
these risks and uncertainties, readers are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
Except as required by law, Delivra disclaims any intention and
assumes no obligation to update or revise any forward-looking
statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking statements or otherwise.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
SOURCE Delivra Corp
